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Background: Both differential expression (DE) and differential co-expression (DC) analyses are appreciated as useful
tools in understanding gene regulation related to complex diseases. The performance of integrating DE and DC,
however, remains unexplored.
Results: In this study, we proposed a novel analytical approach called DECODE (Differential Co-expression and
Differential Expression) to integrate DC and DE analyses of gene expression data. DECODE allows one to study the
combined features of DC and DE of each transcript between two conditions. By incorporating information of the
dependency between DC and DE variables, two optimal thresholds for defining substantial change in expression and
co-expression are systematically defined for each gene based on chi-square maximization. By using these thresholds,
genes can be categorized into four groups with either high or low DC and DE characteristics. In this study, DECODE
was applied to a large breast cancer microarray data set consisted of two thousand tumor samples. By identifying
genes with high DE and high DC, we demonstrated that DECODE could improve the detection of some functional
gene sets such as those related to immune system, metastasis, lipid and glucose metabolism. Further investigation on
the identified genes and the associated functional pathways would provide an additional level of understanding of
complex disease mechanism.
Conclusions: By complementing the recent DC and the traditional DE analyses, DECODE is a valuable methodology
for investigating biological functions of genes exhibiting disease-associated DE and DC combined characteristics,
which may not be easily revealed through DC or DE approach alone.
DECODE is available at the Comprehensive R Archive Network (CRAN): http://cran.r-project.org/web/packages/
decode/index.html.Background
The identification of complex gene connections and
interactions that contribute to the function of living cells
is one of the main challenges in functional genomics and
system biology. Gene expression profiles provide rich
functional information for the study of gene inter-
relationships. An early key approach in analyzing gene
expression data was based on differential expression
(DE). DE analysis has been widely used in many gene ex-
pression studies, in which the main task is to identify
genes that showed different expression levels across
different conditions [1-3]. The motivation is that the* Correspondence: nancytsui.cuhk@gmail.com; ben.yung@polyu.edu.hk
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unless otherwise stated.differentially expressed genes may have roles in the given
phenotypes or conditions, and hence the studying of these
genes may reveal the underlying biological mechanisms.
In particular, DE analysis is a widely adopted approach
that has been successfully applied in cancer research
[4-6]. The analysis is useful in prioritising genes that
may be dysregulated in cancer. It is popularly used in
some challenging problems such as in identifying cancer-
specific biomarkers for distinguishing patients and normal
subjects, and in identifying potential candidate genes that
response to drug treatment and environmental toxins,
which will provide illuminative insight on better diag-
nosis and treatment of diseases at molecular level
[4,5,7,8].s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and their potential interactions are ignored. Biomole-
cules such as genes, RNAs and proteins do not act alone;
they coordinate as functional modules in biological pro-
cesses and signalling pathways. They also physically
aggregate to form nano-machineries such as ribosomes,
chaperone and spliceosome to carry out specific func-
tions in the cells [9]. Genes participate in same bio-
logical process tend to have similar expression pattern as
demonstrated by numerous genome-wide expression
studies [10-15]. Furthermore, evidence from previous
studies showed that activating a metabolic pathway by
small increasing expressions of many genes can be more
substantial than a significant over-expression of an indi-
vidual gene [16,17]. To address the gene independence
model in DE analysis, approaches based on gene
co-expression, gene sets, and gene clustering have been
emerged. They were utilized to explore patterns of
RNA expression, and hence intrinsic gene interactions
[10-12,18-25].
Extending the gene co-expression concept, the analysis
of differential co-expression (DC) has gained much at-
tention in recent years [26-29]. It aims to gain insights
into altered regulatory mechanisms between classes,
such as disease and healthy controls, by studying their
difference in gene co-expression patterns. The analysis is
based on the rationale that co-regulated genes tend to
share similar expression patterns. As complement to DE
analysis, DC analysis is useful in identifying disease
genes that may not show significant changes in expres-
sional levels. One possible biological explanation is that
given a disease gene, mutations in its coding region or
post-translational modifications such as methylation, ubi-
quitination, and glycosylation, can impair its interac-
tions with other gene counterparts without alternating
expression level [26,30].
Evidence from previous studies showed that both DE
and DC analyses are useful in identifying functionally
important genes. From an informatics perspective, we
questioned if relationship exists between these two types
of information. Conceptually, if the two approaches
extract independent information, we can simply deploy
them separately and obtain distinct pieces of information
(i.e. two statistically independent gene lists). On the
other hand, if they extract dependent information, from
a biological perspective, we seek for biological reasons
such as cellular functions correspond to such depend-
ency. Furthermore, we evaluated whether combining DE
and DC criteria would improve the selection of func-
tional relevant genes. The integrated DE and DC infor-
mation may provide new opportunities for dissecting
complex disease mechanism.
The benefit of integrating DC and DE approaches has
been demonstrated by the study of Hudson et al. thatcompared two groups of cattle with or without a known
mutation on the transcriptional regulator, namely the
myostatin [31]. While no significant difference in myos-
tatin mRNA levels was found between the two groups,
myostatin was ranked the most important among 920
transcriptional regulators according to a scoring function
that incorporates DC, DE, and expression level. After de-
tailed examination of the scoring system of Hudson et al.,
we concerned that the differential co-expression term was
squared in the score in which the reason was unclear.
Moreover, the DE genes were selected using a rather
conservative statistical criterion, such that only 85 out
of 11,057 genes were identified to be significant.
When integrating DE and DC approaches, one chal-
lenging problem is to define appropriate thresholds for
selecting high DE genes and high DC gene pairs. Apply-
ing over-stringent thresholds may filter out many useful
genes and gene pairs; whereas over-relaxing thresholds
may lead to high false positivity. This problem is more
apparent in DC analysis. Consider an expression data of
m genes, the number of unique gene pairs is m(m − 1)/2.
Such huge number of gene pairs makes most multiple
testing procedures powerless [32]. As a result, DC gene-
pair selection methods were usually based on ad hoc cri-
teria, such as by considering the highest n% of gene pairs
[27] or by using pre-defined constant thresholds [33].
In this study, we have developed a novel DECODE
(Differential Co-expression and Differential Expression)
analytical approach that coherently integrates DC and
DE aspects. In particular, DECODE aims to improve the
identification of functional gene sets or pathways that
may be missed out by DC or DE criterion alone. We sys-
tematically defined DC and DE thresholds based on the
dependency pattern between DE and DC variables. The
functional relevance of the identified genes was also
evaluated.
Methods
DECODE consists of four steps: (1) calculating differential
expression (DE), (2) calculating differential co-expression
(DC), (3) selecting thresholds to define high or low values
of DC and DE variables based on chi-square maximization,
and statistically evaluating partitions divided by the thresh-
olds, (4) comparing functional relevance of genes cate-
gorized into the partitions of high DC, high DE, or
both. Figure 1 illustrates the overview of the analytical
framework. Details are described in the following
sections.
Differential Expression (DE)
Consider a gene expression data set with m genes from
samples of two states (or classes): one state consists
of case (e.g. disease) group xD, while the other consists
of control (e.g. normal or healthy) group xN. We used
Figure 1 Overview of DECODE. (i) Calculating DE for every gene. (ii) Consider every individual gene i in turn, calculating DC between gene i with
every other genes. Genes are represented by nodes. Higher DC between a gene and gene i is illustrated using longer edge. (iii) Selecting optimal
thresholds to define high/low DE and high/low DC based on chi-square maximization. Genes with higher DE are illustrated by shading with deeper
red colour. (iv) Evaluate functional relevance of selected gene partitions based on functional gene sets.
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differential expression of each gene. The t-value mea-
sures the difference of expression levels, in units of
standard deviations, between the two states. A positive
t-value (disease vs. normal) of a gene indicates an
up-regulation in disease state; whereas a negative value
indicates a down-regulation. A higher absolute t-value
indicates a larger DE difference. The absolute t-value
|ti| for a given gene i, where i∈{1,…,m}, is defined as:
tij j ¼ xD− xNj jffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sD2
nD
þ sN 2nN
q ð1Þ
where xD and xN are mean expression levels in disease
and normal states, nD and nN are sample sizes of disease
and normal states, and sD and sN are standard deviations
of expression levels in disease and normal states.
Our current DECODE algorithm has been designed to
handle gene expression profiles of large sample size be-
cause we have utilized ordinary t-statistic to measure
DE. In the future, DECODE can be readily modified for
expressional analysis of small dataset by incorporating
the moderate t-statistic [34].
Differential Co-expression (DC)
We have adopted a widely used differential co-expression
measure, Z [30,32,35-38]. The Z measure quantifies the
correlation difference between expression levels of twogenes in disease and normal samples. Consider any two
genes i and j in the expression data, let rNij and r
D
ij be the
Pearson correlation coefficient calculated separately over
the samples in normal and disease state, respectively. The
measure for differential co-expression, Zij, between Xi and
Xj is defined as:
Zij ¼
zNij −z
D
ij
 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
nN−3
þ 1nD−3
q ð2Þ
where nN and nD are sample sizes in the normal and
disease states, zNij and z
D
ij are the Fisher-transforms of the
correlations for rNij and r
D
ij , respectively, they are defined as:
zNij ¼
1
2
ln
1þ rNij
1−rNij

 ð3:1Þ
zDij ¼
1
2
ln
1þ rDij
1−rDij

 ð3:2Þ
After the transformation, zNij and z
D
ij are both approxi-
mately normally distributed [39,40].
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based on chi-square (χ2) maximization
With DE and DC measures defined, we investigated the
relationship between DE and DC for every gene in the
expression data in turn. Given m genes in the expression
data, there are m pairs of relationships between DE and
DC for consideration. Specifically, consider an individual
gene i in the data, we explored the relationship between
DE of every gene and DC between gene i and every
other genes. Figure 2 illustrated some possible relation-
ships using scatterplots.
Next, for each gene i, we questioned whether genes
with higher DC to gene i tends to (or tends not to) have
higher DE. To address this, we identify two thresholds
for gene i. One is used for defining high or low DE; an-
other is used for defining high or low DC. We selected
these two thresholds for each gene based on chi-square
(χ2) maximization. In general, a Pearson’s chi-square test
is used to evaluate the dependency between two vari-
ables. For our purpose, the chi-square test is also used
for selecting two optimal thresholds, one for each vari-
able, such that the strongest statistical dependencies be-
tween the DE and DC variables can be observed.
Defining a variable into three or more categories or
comparing chi-square measure with other discretizing
measures such as entropy based measure [41] is out of
the scope of current study.
The threshold selection algorithm based on chi-square
maximization is described as follows. Given m genes in
the expression data, for each gene i, we seeked for a pair
of optimal thresholds, zi and t

i for the DC and DE vari-
ables respectively. The pair of optimal threshold is se-
lected from a set of threshold candidates, {(zij, tj)} where
j = {1,…,m}. Consider each pair of threshold candidates
in turn, every gene k where k = {1,…,m} can be catego-
rized into one of following four partitions as illustrated
in Figure 3 including (1) low DC and low DE (or
LDC_LDE), denoted as SLDC_LDE, (2) high DC and low
DE (HDC_LDE), SHDC_LDE, (3) low DC and high DEFigure 2 Some possible relationships between differential expression (DE)
represents a gene. (a) Positive relationship (b) Negative relationship (c) No(LDC_HDE), SLDC_HDE, (4) high DC and high DE
(HDC_HDE), SHDC_HDE. They can be formally defined as:
SLDC LDE ¼ zik; tk
 
;where zik < zij and tk < tj
 
ð4:1Þ
SLDC HDE ¼ zik; tk
 
; where zik < zij and tk≥tj
 
ð4:2Þ
SHDC LDE ¼ zik; tk
 
; where zik≥zij and tk < tj
 
ð4:3Þ
SHDC HDE ¼ zik; tk
 
; where zik≥zij and tk≥tj
  ð4:4Þ
Based on these four partitions, a two by two contin-
gency table (Table 1) can be constructed in which the
number of observed genes in each partition can be
counted. The observed frequency for each partition can
formally be defined as:
obsA B ¼ SABj j ð5Þ
where A = {low DC, high DC}, B = {low DE, high DE}.
Given the contingency table, the chi-square value, χ2k ,
for gene k can be computed as follows:
χ2k ¼
X
A¼ low DC; high DCf g
X
B¼ low DE; high DEf g
obsA B−expA B
expA B
 	2
ð6Þ
where obsA_B and expA_B are the observed and ex-
pected frequency respectively. Assume the two DE and
DC variables are independent, the expected frequency
can be calculated using the marginal totals of the contin-
gency table (Table 1). They can be computed as follows:
expA B ¼
obsAobsB
m
ð7Þ
The pair of threshold candidate, zi and t

i , that gives
maximum chi-square value is then selected as theand the differential co-expression (DC) with gene i. Each point
significant relationship.
Figure 3 Genes are divided into four partitions based on the optimal
DC and DE thresholds. The four divided partitions are (1) low DC and
low DE (or LDC_LDE), (2) high DC and low DE (HDC_LDE), (3) low DC
and high DE (LDC_HDE), and (4) high DC and high DE (HDC_HDE).
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expression data, we perform the same procedure above
and obtain their optimal threshold pairs. The chi-square
maximization threshold selection procedure can be sum-
marized as follows:
(1)For every gene iTabl
High
Low
Marg(1.1) For every pair of threshold candidates
(1.1.1) Based on current threshold candidate, all
genes can be divided into 4 partitions
includinge 1
DE
DE
ina Low DC and low DE
 Low DC and high DE
 High DC and low DE
 High DC and high DE
(1.1.2) From the four partitions, construct a 2 × 2
contingency table to count their observed
frequencies.2×2 contingency table for DE and DC
Low DC
(LDC)
High DC
(HDC)
Marginal total
for DE
(HDE) obsHDE_LDC obsHDE_HDC obsHDE
(LDE) obsLDE_LDC obsLDE_HDC obsLDE
l total for DC obsLDC obsHDC(1.1.3) Compute the chi-square value based on
the contingency table.
(1.2) Select the threshold candidate pair with
maximized chi-square value as the pair of optimal
thresholds for gene i.We further evaluated the statistical significance for the
association between DC and DE for every gene i. For
every chi-square value generated in the above procedure,
a corresponding p-value can also be obtained based on
the chi-square distribution. The p-values have to be
adjusted for multiple testing. First, for every gene i, since
the chi-square tests are performed for m possible thresh-
old candidates, there are m tests in total. Here, the p-
values are adjusted using Bonferroni corrections [42].
Next, since a maximum chi-square value is used for
selecting the optimal thresholds for every gene i, there
are m maximum chi-square values in total for compari-
sons. We further corrected the adjusted p-values using a
less stringent Benjamini and Hochberg’s method [43]. In
later section, we evaluated the false positive control of
these adjustments using simulated data.
The chi-square test only examines the significance of
the association between DC and DE variables. However,
to further evaluate whether the association between high
DC and high DE is significant, adjusted residual can be
used [44]. If the observed number of genes (formula 5)
found in high DC and high DE partition is higher than
the expected frequency (formula 7), the association be-
tween high DC and high DE is regarded as positive.
Conversely, if observed frequency is less than expected,
the association is regarded as negative.
When the gene partitions are identified based on the
optimal thresholds, they provide a flexible framework to
study genes with different DC and DE characteristics.
For instance, to understand the functional roles of the
selected genes in a partition, gene set analysis can be
performed. Furthermore, not only these gene partitions
can be examined individually, studying on the combina-
tions of partitions is also possible. Figure 4 illustrates
some possible combinations. For example, by combining
high DC and high DE partition (HDC_HDE) with high
DC and low DE partition (HDC_LDE), the resulting par-
tition is high DC (HDC), which can be regarded as a
partition selected by using a single or individual high
DC criterion.
Evaluating functional relevance
For a gene partition identified with specific DC and DE
characteristics in previous step, we further examined the
functional relevance of the partition genes using known
functional gene sets. Pre-defined gene sets from Gene
Ontology (GO) sets [45,46], Reactome pathways [47]
and KEGG pathways [48,49] were used in the current
Figure 4 Some possible partitions by combining individual partitions. (a) High DC (HDC) only. (b) High DE (HDE) only. (c) Low DC (LDC) only.
(d) Low DE (LDE) only.
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hyper-geometric distribution is conducted to determine
whether a set of partition genes is significantly over-
represented in a functional gene set.
To simplify the analysis and interpretation, for each
gene partition, only the best associated functional gene
set was considered instead of all significant gene sets.
Given a partition, the best associated gene set can be
defined as the most significant gene set associated to the
partition with lowest p-value computed from the Fisher’s
exact test. The p-values have to be adjusted for multiple
testing. First, suppose the number of pre-defined func-
tional gene sets is k, there are k tests between a gene
partition and the gene sets. The p-values are then ad-
justed using Bonferroni corrections [42]. Next, consider
m’ selected gene partitions, there are m’ best associated
gene sets. The p-values are further adjusted using a less
stringent Benjamini and Hochberg’s method [43].
To facilitate the comparison of adjusted p-values from
different partitions obtained in gene set analysis, a meas-
ure, referred to as functional information (FI), was used
to quantify the significance of association between a
gene’s high DC and high DE partition SHDE_HDC (for-
mula 4.4) and a functional gene set G. It is defined as:
FISHDE HDC ;G ¼ −log2 pð Þ ð8Þ
where p is the adjusted p-value. When the significance
of the association is high, p is small and in turn FI is
high.
In this study, we questioned whether the functional in-
formation yielded from a partition selected based on the
combining criteria of high DC and high DE is higher
than that based on either of the individual high DC or
high DE criterion alone. For a fair comparison, we con-
sidered the thresholds of individual criteria were the
same as the optimal threshold pairs, zi and t

i , obtained
from the DC and DE criteria for each gene i as described
in the previous section.The gain of functional information by combining the
high DC and high DE criteria over an individual criter-
ion of DE for a given gene set G can be defined as:
Δ
0
G ¼ FISHDC HDE ;G−FISHDE ;G ð9Þ
where FISHDE ;G is the functional information for the as-
sociation between a high DE gene partition SHDE and the
function gene set G.
Similarly, the gain of functional information by com-
bining the DC and DE criteria over an individual criter-
ion of DC for a given gene set G can be defined as:
Δ
00
G ¼ FISHDC HDE ;G−FISHDC ;G ð10Þ
where FISHDC ;G is the functional information for the as-
sociation between a high DC gene partition SHDE and
the function gene set G.
To highlight the functional information gain by com-
bining DC and DE criteria over individual DC or DE cri-
teria for a given gene set G, the minimum of individual
FI gains can be computed using formula 9 and formula
10, which is defined as:
ΔG ¼ min Δ
0
G;Δ
00
G

 
ð11Þ
The minimal FI gain is high only when both of the in-
dividual gains are high. It is low when any one of the in-
dividual gains is low. A negative gain means FI based on
the combining criteria is lower than either one or both
of the individual criteria.
Sample size estimation
The method uses three common statistical measures
including t-statistic, differential co-expression measure
based on z-transform of correlation coefficient, and chi-
square statistics. For t-statistics, the sample size require-
ment depends on factors including alpha-level (α), power
(1-β), and the anticipated effect size (Cohen’s d) [51].
For example, consider α = 0.05, 1-β = 0.8, and d = 0.5, the
minimum sample size for a two-tailed t-test is 128. For
Figure 5 The distributions of the maximum chi-square values for dif-
ferent m number of genes.
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1-β = 0.8, the difference between two Fisher’s z trans-
forms is 0.5, the minimum sample size for a two-tailed
t-test is 87 [52]. The chi-square test is used to catego-
rized the genes into high/low DC and DE. In applying
the test on a 2 × 2 table, the expected frequencies in
every cells are required to be greater than 3 or 5. In
these examples, the overall minimum sample size re-
quired would be 128 given the specification on the
expected significant level and power.
Results and discussion
Simulation study
The proposed DECODE method provides a way to select
thresholds for DC and DE variables for every gene based
on chi-square maximization. Based on the maximum
chi-square values, the significance of the dependencies
between the DC and DE variables were evaluated. The
p-values were adjusted for multiple testing as described
in the method session. We performed simulation to test
whether significantly high maximum chi-square values
can be generated by chance even when DC and DE were
independent. In addition, we evaluated whether the
p-value adjustment provided good control on false posi-
tives rate.
DC and DE variables were simulated for different
number of genes (m) including 10000, 15000, 20000,
and 25000. For each of the m genes, we simulated m
pairs of random t and Z values for the DC and DE vari-
ables respectively. The random t and Z values are simu-
lated independently. Since DE measure, calculated based
on t-statistics (formula 1), follows a t-distribution, the
random t-values were generated based on t-distribution.
The DC measure, calculated based on Fisher-transforms
of the correlations (formula 2), are approximately nor-
mally distributed [40,53]. Here, the random Z values
were generated based on normal distribution. All gener-
ated t and Z values were then converted to absolute
values. Next, we performed chi-square maximization on
these m pairs of DC and DE values.
The distribution of the maximum chi-square values
for different m was shown in Figure 5. The average max-
imum chi-square values and maximum chi-square values
at α = 0.05 were shown in Table 2. Since DE and DC
variables were simulated independently, any significant
results were regarded as false positives. For example,
consider m = 10000, the highest 500 chi-square values
were false positives at α = 0.05. When p-values of max-
imum chi-square values were not adjusted, all 10000
values were significant with confident level of 0.05 as
their values greater than the corresponding tabulated
value of 3.841.
To control these false positives, first adjustment was
made for selecting maximum chi-square values from10000 chi-square values using Bonferroni corrections.
This resulted in 155 maximum chi-square values with
adjusted p-value less than 0.05. In other words, there
were 155 false positives. Second adjustment based on
Benjamini and Hochberg’s method was then made when
comparing 10000 maximum chi-square values. This
resulted in only 4 false positives. Results for other values
of m were shown in Table 2. From the simulation, high
maximum chi-square values could be observed because
of multiple testing. We showed that the p-value adjust-
ments could provide a stringent control on the false
positive rate.
DECODE analysis on breast cancer data
Design of experiment
We aimed to systematically determine whether the com-
bining high DC and high DE (or HDC_HDE) criteria
outperform individual criteria in selecting functional
relevant genes. Specifically, after the best associated gene
set was identified for each significant partition and the
corresponding functional information was obtained, we
evaluated whether the functional information based on
the HDC_HDE criteria was higher than that based on
individual HDC or HDE criteria.
Data sets
Breast cancer data of 25236 genes consisted of 1992
breast tumor samples and 144 normal samples was
obtained from European genome-phenome archive [53].
From their study, the tumor data was pre-defined into
two random subsets including a discovery set and a
validation set. Here, we also randomly split the normal
samples into 2 subsets, each with 72 samples. Conse-
quently, we conducted DECODE analysis on two inde-
pendent sets of tumor and normal samples including a
discovery vs. normal set and a validation vs. normal set.
The validation vs. normal set was used for evaluating
the reproducibility of DECODE in detecting functional
Table 2 The false positive control using the p-value adjustments on simulated data
# of genes (m) Average of maximum
chi-square value
Observed max.
chi-square at α = 0.05
# of false positive
at α = 0.05
# of sig. genes after
1st adjustment
# of sig. genes after
2nd adjustment
10000 11.38 17.70 500 155 4
15000 11.79 17.97 750 215 7
20000 12.10 18.36 1000 231 13
25000 12.27 18.56 1250 280 11
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is an artifact, we also performed the same analysis using
a normal vs. normal set in which both of the case and
control groups are the two independent sets of 72 nor-
mal samples.
In evaluating the functional relevance of selected
genes in the analysis, a total of 7114 functional gene sets
were used, including 5895 sets from Gene Ontology
(GO) sets (as of Jan 14, 2014) [45], 999 sets from Reac-
tome pathways (release 37) [47] and KEGG pathways
(as of July 1, 2011) [48].
Overview of the results
In analyzing the discovery vs. normal set of the breast
cancer data, 17930 genes out of all genes in the breast
cancer data have a significant and positive HDC and
HDE association (adjusted p-value < 0.05). The best
associated gene set was then identified for each gene
partition of these positive associations. The number of
unique best associated gene sets found was 99. For each
unique best associated gene set, the mean minimum
FI gains were calculated.
Comparing distribution of average functional information
of HDC_HDE partitions in normal vs. normal set
Among the HDC_HDE partitions of 17930 genes se-
lected from the discovery vs. normal set, we investigated
the distribution of functional information of their best
associated gene sets and compared it to those using indi-
vidual HDC or HDE criteria. The distributions were
shown in Figure 6a. From the figure, a noticeable obser-
vation is that when using the HDE criteria, a large group
of 1609 partitions were obtained at a high functional in-
formation between 120 and 125. Despite of such large
group, these partitions were only best associated to two
functional gene set including “Cell Cycle (REACT_115566)”
and “Cell Cycle, Mitotic (REACT_152)”. In general, the
functional information obtained using HDC criteria was
lower than HDE or HDC_HDE criteria for these se-
lected partitions.
To determine whether the functional information ob-
tained was an artifact, we performed the same analysis
to the normal vs. normal set. Out of all genes, only 6870
genes have a significant and positive HDC and HDE
association (adjusted p-value < 0.05), compared to 17930in the discovery vs. normal set. This difference was ex-
pected because the gene co-expressions were less differ-
ential when using the normal vs. normal set. Figure 6b
showed the distribution of the function information of
the best associated gene sets obtained for the selected
6870 partitions using different criteria. In comparing
Figure 6a and b, the levels of functional information
obtained were apparently lower when using the normal
vs. normal set.
HDC_HDE vs. individual HDC or HDE criteria
Figure 7 showed the top 10 best associated gene sets
with highest mean minimum FI gain for HDC_HDE
partitions. More detail results were shown in Additional
file 1: Table S1. The combined HDC_HDE criteria out-
performed both of the individual criteria in six gene sets,
as marked by both red and blue asterisks in Figure 7. An
investigation of these gene sets provided useful insights
on the mechanisms that are highly altered and highly
activated (or inhibited) in breast cancer.
Among the identified gene sets, cellular response to
type I interferon (GO:0071357) and regulation of T cell
activation (GO:0050863) (Figure 7), are related to the
immune response system. Type I interferons are key
coordinators of the interactions between tumors and the
immune system [54]. They regulate innate and adaptive
immune responses such as the activation, migration,
differentiation and survival of immune cells including
macrophages, monocytes, NK cells, dendritic cells, B
cells and T cells [55]. Furthermore, type I interferon re-
sponse also plays an important role in preventing breast
cancer spread to the bone [56].
Cell-cell junction (GO:0005911), regulation of cell adhe-
sion (GO:0030155), and adherens junction (GO:0005912)
(Figure 7) are closely related to metastasis in cancer.
Metastasis is the process by which cancer spreads from
the place of a primary tumor to distant locations in the
body. The cell adhesion molecules play a crucial role in
metastasis by promoting cell-cell interactions between
tumor cells and the endothelium in distant tissues [57].
Lipid particle (GO:0005811), monocarboxylic acid meta-
bolic process (GO:0032787), monosaccharide metabolic
process (GO:0005996), and glucose metabolic process
(GO:0006006) are related to lipid and glucose metabolism
in breast cancer. In breast cancer, metabolisms including
Figure 6 Distribution of function information for different gene partitions using (a) discovery vs. normal set, and (b) normal vs. normal set.
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which happen as a result of mutations in cancer genes and
alterations in cellular signalling [59]. A well-known meta-
bolic rewiring in cancer is an increase of glucose uptake
but a decrease in the proportion of glucose oxidized [60].
These rewired cancer metabolisms maintain the fitness of
tumour cells for rapid proliferation and growth [59].
An increased understanding of these innate immune
triggers, metastasis mechanisms, and cancer metabo-
lisms can be important in developing new therapeutic
strategies aimed at promoting immune responses against
tumors, preventing metastasis, and targeting metabo-
lisms in cancer cells. Remarkably, our proposed method
was useful in detecting these functions that exhibit high
DC and high DE characteristics in breast cancer. The
detection on these functional gene sets based on com-
bining criteria outperformed that based on individual
high DC or high DE criteria alone.Detecting association between Type I interferon and TRIM22
Next, to illustrate the DC and DE analysis in more
detail, we selected the first ranked best association gene
set for further exploration. As shown in Figure 7, the
first ranked gene set was “cellular response to type I
interferon”. It was the best associated gene set of a total
of 27 HDC_HDE partitions. Among these partitions,
those of the gene TRIM22 attained highest minimum FI
gain of 20.5. Specifically, the gene set was associated to
the HDC_HDE, HDC, and HDE partitions with the
adjusted p-values of 2.73 × 10−18 (FI = 58.3 bits), 4.18 ×
10−12 (FI = 37.8), and 1.85 × 10−2 (FI = 5.8) respectively.
The average expression of TRIM22 in disease state was
significantly lower than that in normal state with FDR of
4.54 × 10−22. It ranked 3166 among 18007 significant
differential expressed genes (FDR <0.05). Figure 8
showed the scatterplots of DE and DC for TRIM22. The
optimal thresholds were selected based on chi-square
Figure 7 Top 10 best associated gene sets with highest mean minimum functional information (FI) gain, ΔG , for HDC_HDE partitions in breast
cancer data (discovery vs. normal set). The HDC_HDE partitions (in green) yield significantly higher mean FI than HDC partitions (in red) or HDE
partitions (in blue) are marked by red or blue asterisks respectively. The combining HDC_HDE criteria outperformed both of the individual criteria
in six gene sets (marked by both red and blue asterisks).
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were 2.263 and 5.654 respectively, which were repre-
sented using red dash lines in Figure 8. Figure 8a
showed a heatmap for the chi-square values for each
pair of threshold candidates. The optimal point was
placed in the region of the high chi-square values. The
high chi-square values were more spread horizontally
along the DC than vertically along the DE dimension. It
may implicate a narrower range of DE for detecting
high DC and DE dependency in this case. With the opti-
mal thresholds, genes were divided into four partitions
including HDC_HDE (999 genes), HDC_LDE (1090
genes), LDC_HDE (8403 genes), and LDC_LDE (14744
genes). The number of genes in HDC_HDE (999) was
significantly more than the expected number (778.3)
with adjusted p-value of 7.49 × 10−21. Genes of “cellular
response to type I interferon” in these four partitions
were highlighted using triangle as shown in Figure 8b.
The scatterplot of differential expression (DE) and cor-
relation between genes and TRIM22 in breast cancer
state and in normal state were shown in Figure 9a and b
respectively. Most selected genes in HDC_HDE parti-
tion, colour in red, were more positively correlated
with TRIM22 in the breast cancer state (Figure 9b) in
compare to the normal state (Figure 9a). Twenty-three
out of twenty-seven (85.2%) selected genes in the
HDC_HDE partition attained a higher expression in dis-
ease state whereas the remaining four genes attain a
higher expression in normal state. A network between
TRIM22 and the genes of cellular response to type I
interferon was shown in Figure 10.
TRIM22, tripartite motif-containing 22, previously
known as Staf50 (stimulated transacting factor 50 kDa),is a member of the tripartite motif (TRIM) subfamily
of RING finger proteins. TRIM22 underwent self-
ubiquitination in vitro and in vivo, suggesting its func-
tional role as a RING finger E3 ligase [61]. Remarkably,
the identified relationship between TRIM22 and type I
interferon was coherent to previous experimental find-
ing [62-65]. TRIM22 was reported to be inducible by
type 1 IFN in vitro [62,65]. The association between
TRIM22 and type 1 IFN expression in vivo was recently
identified in HIV studies [63,64]. TRIM22 was sug-
gested as an antiviral effector in vitro and in vivo
[63,64]. The expression of TRIM22 was found to be
negatively correlated with plasma HIV viral load but
positively correlated with CD4-cell counts in primary
HIV-1 infection. Silencing of TRIM22, in the presence
of IFN-α, could increase HIV infection and virus re-
lease. These evidences supported the immune pressure
of TRIM22 against HIV-1. Moreover, TRIM22 is a p53
target gene and contribute to viral defence by restric-
tion of viral replication [66]. Although the promoter
region of TRIM22 is not p53-responsive, a p53-
responsive motif is located in intron 1 of TRIM22. The
over-expression of TRIM22 can moderate the clono-
genic growth of leukemic U-937 cells suggests an anti-
proliferative role of leukemic cells. Since TRIM22 is
inducible by both p53 and type I IFN, it may involve in
the crosstalk of p53 related pathways and interferon
pathways. In short, we demonstrated that the proposed
method can generate hypothesis on the relationship
between a gene and its associated functional gene sets
with high DC and high DE characteristics, plausibly im-
plicated some rewired biological functions in breast
cancer for follow-up investigations.
Figure 8 The scatterplot of DE and DC for TRIM22. Each point in the plot represents a gene. The x-axis represents the absolute value of DC, |Z|,
between a gene and TRIM22. The y-axis represents the absolute value of DE, |t|, of a gene. The optimal thresholds for DC and DE are drawn using
red dash lines. (a) Heat map of the chi-square values (χ2) for the threshold candidates. (b) Gene set “cellular response to type I interferon (GO:0071357)”
is best associated to the HDC_HDE partition (Adjusted p-value =2.73 × 10−18). Genes found in “cellular response to type I interferon” are highlighted
using triangles. These genes with different DC and DE values are highlighted in different colours: high DC and high DE (red); high DC and low DE
(blue); low DC and high DE (green); low DC and low DE (pink).
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To evaluate the reproducibility of DECODE, we ana-
lyzed the validation vs. normal set of the breast cancer
data. Out of all genes, 19302 genes were found to have a
significant DC and DE association (adjusted p-value <
0.05). The best associated gene set was then identified
for each gene partition of these positive associations.
The number of unique best associated gene sets was 88.
Additional file 1: Figure S1 showed the top ten best
associated gene sets with highest mean minimum FI gain
in using high DC and high DE criteria. The detail of theresults was shown in Additional file 1: Table S2 in which
the top 30 results were included.
Figure 11 showed the venn diagram in comparing the
number of selected gene sets from the discovery set and
validation set for the high DC and high DE criteria.
Considering the HDC_HDE partitions, 72 unique best
associated gene sets were commonly identified, which
corresponded to 72.7% of the 99 gene sets and 81.8% of
the 88 gene sets identified from the discovery vs. normal
and validation vs. normal data sets respectively. Overall,
it showed that a substantial number of functional gene
Figure 9 The scatterplot of differential expression (DE) and correlation between TRIM22 and every gene in (a) breast cancer state and (b) in
normal state. Each point in the plot represents a gene. The x-axis in (a) and (b) represents the correlation coefficients, rN and rD, between TRIM22
and every gene in breast cancer state and normal state respectively. The y-axis represents the DE, t, of the gene. A positive t value indicates a
higher gene expression in disease state in compare to normal state, and vice versa, a negative t value indicates a lower gene expression in disease state
in compare to normal state. The optimal threshold for DE is drawn using red dash line. Genes found in “cellular response to type I interferon”
are highlighted using triangles. Similar to Figure 8, these genes with different DC and DE values are highlighted in different colours: HDC_HDE
(red); HDC_LDE (blue); LDC_HDE (green); LDC_LDE (pink).
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using two independent data sets of large samples.
DECODE analysis on Malaysian breast cancer data
In additional to the European breast cancer data ob-
tained from European genome-phenome archive, we
have performed the same analysis on an independent
set of breast cancer data. The Malaysian cancer data of
13210 genes consisted of 43 tumor samples and 43
normal samples was obtained from GEO Database,
accession number GSE15852 [67]. By comparing the
results obtained from the European and Malaysian data,common re-wired mechanisms in breast cancer among
patients from these two nationality groups may be
revealed.
By using DECODE, 8780 genes out of all genes in the
data have a significant and positive HDC and HDE associ-
ation (adjusted p-value < 0.05). The best associated gene
set was then identified for each gene partition of these
positive associations. The number of unique best associ-
ated gene sets found was 54. For each unique best associ-
ated gene set, the mean minimum FI gains were calculated.
Additional file 1: Figure S2 showed the top 10 best
associated gene sets with highest mean minimum FI gain
Figure 10 The network betweenTRIM22 and genes of cellular response to type I interferon. Higher DC between a gene and TRIM22 is reflected
using longer edge. Genes with higher DE are shaded using deeper red colour. Genes with different DC and DE values are circled with different
colours: HDC_HDE (red); HDC_LDE (blue); LDC_HDE (green); LDC_LDE (pink).
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in Additional file 1: Table S3. The combining HDC_HDE
criteria outperformed both of the individual criteria in ten
gene sets, as marked by both red and blue asterisks in
Additional file 1: Figure S2. Among the top 10 identified
gene sets, cellular lipid catabolic process (GO:0044242),
monosaccharide metabolic process (GO:0005996), andFigure 11 Venn diagrams in comparing the number of selected
functional gene sets from the discovery vs. normal set and validation
vs. normal set of the breast cancer data using the high DC and high
DE criteria. The numbers of common functional gene sets, those
found in the discovery vs. normal set, and those found in the
validation vs. normal set are shown within the green, blue, yellow
shaded areas respectively.glycerolipid catabolic process (GO:0046503) are related to
the lipid and glucose metabolism, which is consistent to
the results obtained from the European breast cancer data.
The finding hence indicate the importance of the lipid and
glucose metabolic processes in relation to breast cancer.
Conclusions
We presented a novel method named DECODE as a
mean to integrate the DC and DE analysis. DECODE
provides an analytic framework for studying different
DC and DE characteristics of the genes. By incorporat-
ing dependency between DC and DE, high or low values
of the DC and DE variables are systematically defined by
selecting optimal thresholds that maximize the chi-
square value. In using the optimal thresholds, genes can
be divided into partitions with different DC and DE
characteristics. The statistical significance of a gene
partition can further be evaluated by residual test. Note-
worthy, since the identified gene partitions at this stage
are not constrained or depended on any predefined
functional modules or pathways, they provide the oppor-
tunities for the discovery of novel disease related genes.
DECODE is useful for investigating whether the func-
tional information of an identified gene partition using
the combining DC and DE criteria is higher than that
using individual DC or DE criteria alone. In other words,
it may generate critical novel biological insights which
may not be easily obtained using individual DC or DE
Lui et al. BMC Bioinformatics  (2015) 16:182 Page 14 of 15approach. In applying DECODE to the breast cancer
data, we demonstrated that it can improve the detection
of some immune system, metastasis, lipid and glucose
metabolism related gene sets using high DE and high
DC criteria. Further investigation on the identified gene
partitions and the associated functional pathways pro-
vides a more systematic understanding of complex
disease mechanism, which in turn yields useful insights
in the development of new therapeutic strategies for the
disease. In conclusion, in complementing the DC and
DE analysis, DECODE is a valuable methodology in
identifying functional gene sets exhibiting certain com-
bination of DE and DC characteristics, which serves as a
new tool for future gene expression studies.
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